These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 19260027)
1. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Fagan AM; Head D; Shah AR; Marcus D; Mintun M; Morris JC; Holtzman DM Ann Neurol; 2009 Feb; 65(2):176-83. PubMed ID: 19260027 [TBL] [Abstract][Full Text] [Related]
4. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e. Susanto TA; Pua EP; Zhou J; J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756 [TBL] [Abstract][Full Text] [Related]
6. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Morris JC; Roe CM; Xiong C; Fagan AM; Goate AM; Holtzman DM; Mintun MA Ann Neurol; 2010 Jan; 67(1):122-31. PubMed ID: 20186853 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. Fagan AM; Mintun MA; Shah AR; Aldea P; Roe CM; Mach RH; Marcus D; Morris JC; Holtzman DM EMBO Mol Med; 2009 Nov; 1(8-9):371-80. PubMed ID: 20049742 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
10. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249 [TBL] [Abstract][Full Text] [Related]
11. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470 [TBL] [Abstract][Full Text] [Related]
12. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease. Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185 [TBL] [Abstract][Full Text] [Related]
17. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Landau SM; Lu M; Joshi AD; Pontecorvo M; Mintun MA; Trojanowski JQ; Shaw LM; Jagust WJ; Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396 [TBL] [Abstract][Full Text] [Related]
18. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677 [TBL] [Abstract][Full Text] [Related]
20. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]